2. Immunology/Inflammation
  3. CD73

CD73

CD73

Related Products

PDF 0.28 MB

CD73 (Ecto-5′-nucleotidase) is a 70-kD glycosylphosphatidyl inositol (GPI)-anchored cell surface protein encoded by the NT5E gene that plays a crucial role in switching on adenosinergic signaling. CD73 is an ectonucleotidase which catalyzes the terminal step in extracellular adenine nucleotide breakdown: the conversion of AMP to adenosine. Adenosine, which binds to a discrete family of cell surface receptors to initiate intracellular signaling cascades, has been shown to be anti-inflammatory and vasorelaxant.

CD73 has both enzymatic and non-enzymatic functions in cells: as a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape; moreover, CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other. There is ample evidence to show that CD73 is a key regulatory molecule in cancer development and is overexpressed in many cancers, including leukemia, glioblastoma, melanoma, ovarian cancer, esophageal cancer, prostate cancer and breast cancer.

CD73 Related Products (32):

Cat. No. Product Name Effect Purity
  • HY-136978
    OP-5244 Inhibitor 99.07%
    OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research[1].
  • HY-125286
    AB-680 Inhibitor 99.81%
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity[1].
  • HY-P99039
    Oleclumab Inhibitor 99.80%
    Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity[1][2].
  • HY-137246
    CD73-IN-3 Inhibitor
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research[1].
  • HY-100747
    PSB-12379 Inhibitor 99.54%
    PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human)[1][2].
  • HY-160696
    ORIC-533 Inhibitor
    ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment[1].
  • HY-147592
    CD73-IN-11 Inhibitor
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24)[1].
  • HY-112502C
    MethADP triammonium Inhibitor 99.03%
    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway[1].
  • HY-P99181
    Mupadolimab Inhibitor 99.43%
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1].
  • HY-131435
    CD73-IN-2 Inhibitor
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM[1].
  • HY-145334
    CD73-IN-5 Inhibitor 98.14%
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
  • HY-147591
    CD73-IN-10 Inhibitor
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4)[1].
  • HY-147594
    CD73-IN-13 Inhibitor
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7)[1].
  • HY-147589
    CD73-IN-8 Inhibitor
    CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57)[1].
  • HY-152074
    CD73-IN-14 Inhibitor
    D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8+ cells and shows anti-tumor activity[1]. CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-144072
    MRS4620 Inhibitor
    MRS4620 is a potent CD73 inhibitor, with a Ki of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch[1].
  • HY-147590
    CD73-IN-9 Inhibitor
    CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2)[1].
  • HY-100747A
    PSB-12379 disodium Inhibitor
    PSB-12379 disodium, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human)[1][2].
  • HY-103695
    CD73-IN-1 Inhibitor 99.46%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
  • HY-112502B
    MethADP sodium salt Inhibitor
    MethADP (sodium salt) is a specific CD73 inhibitor.